PCR Market for Life Sciences and Diagnostics (qPCR & dPCR, TMA and Other NAAT)

Apr 12, 2017
427 Pages - Pub ID: KLI15318010
Share this report
 
Online Download $3,995
Departmental Site License (one location, 10 users) $5,995
Global Site License $7,990
PCR Testing Market for Life Sciences and Diagnostics (qPCR, dPCR and other NAAT)

Polymerase chain reaction (PCR) technology was the first of what are now many nucleic acid amplification testing (NAAT) methods that have been developed and commercialized. PCR technology is widely used for both life science (research) market and diagnostic applications, with many companies active in these fields. Real-time PCR (qPCR) has become the most widely used DNA amplification method today. PCR Testing Market for Life Sciences and Diagnostics (qPCR, dPCR and other NAAT) examines the markets for life science and clinical applications of PCR and Other NAAT technologies.

The report contains in-depth information on PCR (qPCR, dPCR and other NAAT), breaking the market opportunity down by type of NAAT, instruments versus consumables, market segment, disease indication, and type of infection, including the following data points:
  • Nucleic Acid Amplification Test Market, Worldwide, 2016 and 2021 (All NAATs: Life Science NAAT Market, Clinical NAAT Market, Other NAAT Market, Total NAAT Market)
  • Life Science PCR Market, Instruments versus Consumables, Worldwide, 2016 and 2021 (Reagents/Consumables, Instruments, Software & Services, Total life science PCR market)
  • Life Science PCR Market, by Type of PCR, Worldwide, 2016 (%) (qPCR, dPCR)
  • Life Science PCR Market, by Type of PCR, Worldwide, 2021 (%) (qPCR, dPCR)
  • Diagnostic PCR and Other NAAT Market by Disease Indication, Worldwide, 2016 and 2021 (Infectious Disease, Oncology, Genetic Testing, Transplantation Diagnostics, Other; Total Diagnostics Segment; Blood Screening; Total Clinical NAAT Market)
  • Diagnostic PCR and Other NAAT Market, by Type of NAAT, Worldwide, 2016 (%) (PCR, TMA, Other NAAT)
  • Diagnostic PCR and Other NAAT Market, by Type of NAAT, Worldwide, 2021 (%) (PCR, TMA, Other NAAT)
  • Diagnostic Infectious Disease PCR and Other NAAT Market by Type of Infection, Worldwide, 2016 and 2021 (Hepatitis, HIV, Healthcare Acquired Infections and Sepsis, Respiratory Pathogens, Sexually Transmitted Diseases and Women’s Health, Tuberculosis, Other, Total)
  • Diagnostic Oncology PCR and Other NAAT Market (Screening, Diagnosis/Prognosis/Personalized Medicine/Monitoring) Worldwide, 2016 and 2021 (Cancer screening market, Cancer diagnostics market, Total cancer NAAT market)
  • Diagnostic PCR and Other NAAT Genetic Testing Market by Market Segment, Worldwide, 2016 and 2021 (Inherited Diseases, Thrombophilia, Pharmacogenomics, Total genetic testing market)
The PCR (qPCR, dPCR and other NAAT) market coverage is regional as well, providing the following geographic breakouts for the infectious disease PCR market, PCR oncology or cancer diagnostics, and PCR genetic testing segment, among others:
  • Life Science PCR Market, by Geographical Distribution (%) (U.S., Europe, Japan, ROW)
  • Clinical PCR and Other NAAT Market by Geographical Region, Worldwide, 2016 and 2021 (United States, Europe, Japan, China, Latin America, Rest of World, Total Clinical NAAT Market)
  • Diagnostic Infectious Disease PCR and Other NAAT Market, Worldwide by Geographical Region, 2016 and 2021 (United States, Europe, Japan, China, Latin America, Rest of World, Total - World)
  • Diagnostic Oncology PCR and Other NAAT Market by Geographical Distribution, Worldwide, 2016 and 2021 (United States, Europe, Japan, China, Latin America, Rest of World, World)
  • Diagnostic Inherited Disease PCR and Other NAAT Market by Geographical Distribution, Worldwide, 2016 and 2021 (United States, Europe, Rest of World, World)
  • Diagnostic Transplantation Diagnostics PCR and Other NAAT Market by Geographical Distribution, Worldwide, 2016 and 2021 (United States, Europe, Japan, Rest of World, World)
  • PCR and Other NAAT Blood Screening Market, by Geographical Distribution, Worldwide, 2016 and 2021 (United States, Europe, Japan, China, Latin America, Rest of World, Total)
Beyond these market size and regional estimates and forecasts for both the life science (research) and diagnostic uses of PCR, the report provides an overview of PCR and other NAAT technologies, in addition to discussion of applications of NAAT in life science and clinical diagnostics.

PCR Testing Market for Life Sciences and Diagnostics (qPCR, dPCR and other NAAT) also includes financial information on deals made by PCR and other NAAT companies, including investments and financing agreements, acquisitions, collaborations, and other agreements

Market drivers and challenges in the nucleic acid amplification test market are discussed as well. Issues of growth, competition, market opportunities, regulation, reimbursement, and prospects for the future are reviewed. Some NAAT-based tests are laboratory developed tests (LDTs); the implications of this are discussed. The clinical NAAT market is driven by the need for the information generated by testing. Market changes such as the emergence of new pathogens (such as the Zika virus), or the increasing problem of antibiotic resistance, or other changes are driving the need for specific tests.

The report contains profiles of companies in the market, reflecting the wide range NAAT products and applications in both the life science PCR market and the clinical PCR market. A wide range of industry players is examined, including companies marketing NAAT instruments and/or consumables to the life science research market, companies developing or marketing in vitro diagnostic (IVD) NAAT platforms and tests to clinical laboratories, diagnostic companies offering NAAT tests as a service via their own CLIA-certified laboratory, companies developing or marketing NAAT platforms and tests for rapid point-of-care or near-patient testing, companies developing or marketing PCR-based sample/library preparation products or test panels for DNA sequencing, companies developing or marketing mass spectrometry platforms that include PCR amplification before analysis by mass spectrometry, and companies developing or marketing other technology platforms that include PCR amplification as an initial or early step. Such companies include:
  • Abbott Laboratories
  • Agena Bioscience, Inc.
  • Agilent Technologies, Inc.
  • Alere, Inc.
  • Amoy Diagnostics Co., Ltd.
  • Asuragen, Inc.
  • Atlas Genetics, Ltd.
  • Autogenomics, Inc.
  • Beckman Coulter, Inc. (A Danaher Corporation Company)
  • Becton, Dickinson And Company (BD)
  • Biocartis Group NV
  • Biofire Diagnostics, LLC. (Acquired by bioMérieux)
  • bioMérieux SA
  • Bio-Rad Laboratories, Inc.
  • Bruker Corporation
  • Canon Biomedical
  • Cepheid (A Danaher Company)
  • Curetis
  • Diasorin S.p.A.
  • Eiken Chemical Co., Ltd.
  • Elitechgroup
  • Genepoc, Inc.
  • Genmark Diagnostics, Inc.
  • Genomic Health, Inc.
  • Grifols
  • Hologic, Inc.
  • Invivoscribe Technologies, Inc.
  • Janssen Diagnostics (Division of Janssen Pharmaceutica NV)
  • Luminex Corporation
  • Mast Group
  • Meridian Bioscience, Inc.
  • Multiplicom NV (Part of Agilent Technologies)
  • Qiagen N.V.
  • Quandx, Inc.
  • Quantumdx Group
  • Quidel, Inc.
  • Qvella Corporation
  • RainDance Technologies, Inc. (Acquired by Bio-Rad Laboratories)
  • Roche
  • Siemens Healthineers
  • Spartan Bioscience, Inc.
  • Stat-Diagnostica
  • T2 Biosystems, Inc.
  • Thermo Fisher Scientific, Inc.
CHAPTER 1: EXECUTIVE SUMMARY


  NUCLEIC ACID AMPLIFICATION TESTING OVERVIEW

  SCOPE AND METHODOLOGY

  MARKET OVERVIEW

Table 1-1: PCR and Other NAAT Market, Worldwide, 2016 and 2021 [All NAATs – Life Science and Clinical Markets] (in millions USD)

  FUTURE PROSPECTS IN THE PCR MARKET


CHAPTER 2: INTRODUCTION

  DEVELOPMENT AND EVOLUTION OF POLYMERASE CHAIN REACTION AND OTHER NUCLEIC ACID AMPLIFICATION TESTS

Development and Evolution of PCR

Other Nucleic Acid Amplification Test Methods

Advances in Nucleic Acid Amplification Technology and Emerging Applications

  POINT-OF-VIEW


CHAPTER 3: TECHNOLOGY TRENDS AND INNOVATION

  POLYMERASE CHAIN REACTION (PCR) – OVERVIEW

  PCR, RT-PCR, and qPCR

Digital PCR

Table 3-1: Selected Companies with Digital PCR Technology (For Research and/or Diagnostic Tests)

Multiplex PCR

Table 3-2: Selected Companies with Multiplex PCR Technology [Note: This is not a comprehensive list of all companies with multiplex 
PCR technology/tests.]

Other Modifications of PCR

Table 3-3: Selected Companies with Innovative PCR-Based Methods

  OTHER  NUCLEIC ACID AMPLIFICATION TEST (NAAT) METHODS

Isothermal NAAT Methods in Clinical Laboratories

Rapid Isothermal NAAT Methods in Decentralized Settings - Near Patient and Point-of-Care

Table 3-4: Companies with Other Nucleic Acid Amplification Test Methods

  PLATFORMS USED IN DIFFERENT NAAT MARKETS – RESEARCH, CLINICAL LABORATORIES, AND POINT-OF-CARE TESTING

Table 3-5: Selected Companies Marketing PCR Instruments/Reagents to the Life Sciences Market

Table 3-6: Selected Companies Marketing NAAT Platforms/Tests to Clinical Laboratories

Table 3-7: Selected Companies with NAAT Platforms and Tests for Decentralized Testing or Point-of-Care Settings

  NEW APPLICATIONS OF PCR – COMBINING PCR WITH OTHER TECHNOLOGIES

  PCR as Part of Sample Prep before DNA Sequencing

Table 3-8: Examples of Companies Using PCR during Sample Prep before DNA Sequencing

  PCR before Mass Spectrometry

Table 3-9: Selected Companies Developing Platforms That Use PCR before Analysis by Mass Spectrometry

Other Technologies Being Used with PCR

Table 3-10: Selected Companies Using PCR with Other Technologies (Beyond Sequencing and Mass Spectrometry)

CHAPTER 4: NUCLEIC ACID AMPLIFICATION TESTS IN RESEARCH AND THE CLINICAL LABORATORY

  RESEARCH APPLICATIONS OF POLYMERASE CHAIN REACTION

  INFECTIOUS DISEASE DIAGNOSTICS

Infectious Disease Diagnostic Tests

Table 4-1: Selected Common Microorganisms Detected by Clinical NAAT Tests

Table 4-2: Selected Companies Marketing PCR/NAAT Infectious Disease Tests (Single or Limited Number of Analytes)

Table 4-3: Selected Companies Marketing PCR/NAAT Syndromic Tests/Panels for Infectious Diseases

Antibiotic Resistance/Susceptibility Testing

Table 4-4: Selected Companies Marketing PCR/NAAT-Based Antibiotic Resistance/Susceptibility Tests

Rapid Near-Patient or Point-of-Care Testing for Infectious Diseases

Table 4-5: Selected Companies Marketing Rapid Near-Patient/Point-of-Care PCR/NAAT Infectious Disease Tests

Table 4-6: CLIA Waived NAAT Infectious Disease Tests

  ONCOLOGY

Cancer Risk

Cancer Screening

Table 4-7: Selected Companies Developing/Marketing Diagnostic Tests for HPV

Table 4-8: Selected Companies Developing/Marketing PCR/NAAT Tests for Cancer Screening (Not including HPV Tests for Cervical 
Cancer)

Cancer Diagnostics (Diagnosis, Prognosis, Monitoring, Response to Therapy)

Table 4-9: Selected Companies Developing/Marketing PCR/NAAT Tests for Diagnosis/Prognosis/Predicting Response to Cancer Therapy

Table 4-10: Selected PCR/NAAT Based, FDA Cleared/Approved Companion Diagnostic Tests

  CARDIOVASCULAR DISEASE

Table 4-11: Selected Companies Developing/Marketing PCR Tests for Risk of Thrombophilia

Table 4-12: Selected Companies Developing/Marketing PCR Warfarin Sensitivity Tests

Table 4-13: Selected Companies Developing/Marketing Other PCR-Based Cardiovascular Tests

  GENETIC TESTING

Inherited (Genetic) Disorders

Table 4-14: Selected Companies Developing/Marketing PCR Tests for Risk of Inherited (Genetic) Disorders

Drug Metabolism – Pharmacogenomics Testing

Table 4-15: Pharmacogenomic Biomarkers in Drug Labeling

Table 4-16: Selected Companies Developing/Marketing PCR Tests for Pharmacogenomics (Drug Metabolism)

  HLA Typing

Table 4-17: Selected Companies Developing/Marketing PCR Tests for HLA Typing

  OTHER CLINICAL APPLICATIONS OF POLYMERASE CHAIN REACTION

Table 4-18: Selected Companies Developing/Marketing PCR Tests for Other Clinical Applications

  TRANSFUSION MEDICINE – BLOOD SCREENING

Table 4-19: Selected Companies Developing/Marketing PCR Tests Transfusion Medicine

  NON-CLINICAL APPLICATIONS OF POLYMERASE CHAIN REACTION

CHAPTER 5: DEALS – POLYMERASE CHAIN REACTION/NUCLEIC ACID AMPLIFICATION TEST COMPANIES

  INVESTMENTS AND FINANCING AGREEMENTS

Table 5-1: Selected Investment and Financing Agreements in NAAT Companies

  MERGERS AND ACQUISITIONS

Table 5-2: Selected Acquisitions of NAAT Companies

  CORPORATE AGREEMENTS AND COLLABORATIONS (NOT INCLUDING PHARMACEUTICAL COMPANIES)

Table 5-3: Selected Agreements between NAAT Companies and Other Companies [Not Including Pharmaceutical Companies]

  COLLABORATIONS/AGREEMENTS WITH PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES

Table 5-4: Selected Agreements between NAAT Companies and Pharmaceutical or Biopharmaceutical Companies

  COLLABORATIONS AND OTHER AGREEMENTS WITH UNIVERSITIES, NON-PROFIT RESEARCH INSTITUTES AND GOVERNMENT

Table 5-5: Selected NAAT Company Agreements with Academic or Other Non-Profit Organizations

CHAPTER 6: MARKET DRIVERS AND CHALLENGES - NUCLEIC ACID AMPLIFICATION TEST MARKET

  ISSUES AND HURDLES FACED BY PCR COMPANIES SELLING TO THE RESEARCH MARKET

  CLINICAL MARKET DRIVERS

  POINT-OF-CARE TESTING MARKET DRIVERS AND CHALLENGES/HURDLES

  COMPETITION FROM COMPANIES UTILIZING PCR AND OTHER NAAT TECHNOLOGIES

  COMPETITION AND MARKET OPPORTUNITIES DRIVEN BY OTHER (NON-NAAT) TECHNOLOGIES

Competition

Opportunities

  REGULATION OF IN VITRO DIAGNOSTICS

  LABORATORY DEVELOPED TESTS

  REIMBURSEMENT

  FUTURE PROSPECTS

Table 6-1: Trends in the Polymerase Chain Reaction/Nucleic Acid Amplification Test Market

CHAPTER 7: PCR MARKET ANALYSIS

  PCR & NUCLEIC ACID AMPLIFICATION TEST MARKET OVERVIEW

Table 7-1: Nucleic Acid Amplification Test Market, Worldwide, 2016 and 2021 [All NAATs –Life Science and Clinical Markets] (in millions 
USD) (Life Science NAAT Market, Clinical NAAT Market, Other NAAT Market, Total NAAT Market)

  LIFE SCIENCE NAAT MARKET

Past and Future Growth of Overall Life Science PCR Market

Figure 7-1: Growth of the Life Science PCR Market (1990 – 2016) [# Abstracts Found per Year in PubMed search for “’polymerase chain 
reaction’ or pcr”] (Accessed March 27, 2017)

Life Science PCR Market – Instruments versus Consumables

Table 7-2: Life Science PCR Market, Instruments versus Consumables, Worldwide, 2016 and 2021 (in millions USD) 
(Reagents/Consumables, Instruments, Software & Services, Total life science PCR market)

Life Science PCR Market – By Geographical Distribution

Figure 7-2: Life Science PCR Market, by Geographical Distribution (%) (U.S., Europe, Japan, ROW)

Life Science PCR Market by Type of PCR

Figure 7-3: Life Science PCR Market, by Type of PCR, Worldwide, 2016 (%) (qPCR, dPCR)

Figure 7-4: Life Science PCR Market, by Type of PCR, Worldwide, 2021 (%) (qPCR, dPCR)

  DIAGNOSTIC PCR MARKET – GLOBAL MARKET

Table 7-3: Clinical PCR and Other NAAT Market by Disease Indication, Worldwide, 2016 and 2021 (in millions USD) (Infectious Disease, 
Oncology, Genetic Testing, Transplantation Diagnostics, Other; Total Diagnostics Segment; Blood Screening; Total Clinical NAAT Market)

Table 7-4: Clinical PCR and Other NAAT Market by Geographical Region, Worldwide, 2016 and 2021 (in millions USD) (United States, 
Europe, Japan, China, Latin America, Rest of World, Total Clinical NAAT Market)

Figure 7-5: Clinical PCR and Other NAAT Market, by Type of NAAT, Worldwide, 2016 (%) (PCR, TMA, Other NAAT)

Figure 7-6: Clinical PCR and Other NAAT Market, by Type of NAAT, Worldwide, 2021 (%) (PCR, TMA, Other NAAT)

  DIAGNOSTIC PCR MARKET MARKET – INFECTIOUS DISEASE

Table 7-5: Diagnostic Infectious Disease PCR and Other NAAT Market by Type of Infection, Worldwide, 2016 and 2021 (in millions USD) 
(Hepatitis, HIV, Healthcare Acquired Infections and Sepsis, Respiratory Pathogens, Sexually Transmitted Diseases and Women’s Health, 
Tuberculosis, Other, Total)

Table 7-6: Diagnostic Infectious Disease PCR and Other NAAT Market, Worldwide by Geographical Region, 2016 and 2021 (in millions 
USD) (United States, Europe, Japan, China, Latin America, Rest of World, Total - World)

  DIAGNOSTIC PCR MARKET – ONCOLOGY

Emerging Market for NAAT-Based Cancer Screening

Cancer Diagnosis/Prognosis/Personalized Medicine/Monitoring Market

Table 7-7: Diagnostic Oncology PCR and Other NAAT Market (Screening, Diagnosis/Prognosis/Personalized Medicine/Monitoring) 
Worldwide, 2016 and 2021 (in millions USD) (Cancer screening market, Cancer diagnostics market, Total cancer NAAT market)

Table 7-8: Diagnostic Oncology PCR and Other NAAT Market by Geographical Distribution, Worldwide, 2016 and 2021 (in millions USD) 
(United States, Europe, Japan, China, Latin America, Rest of World, World)

  DIAGNOSTIC PCR MARKET – GENETIC TESTING

Table 7-9: Diagnostic PCR and Other NAAT Genetic Testing Market by Market Segment (Thrombophilia, Inherited Diseases, 
Pharmacogenomics) Worldwide, 2016 and 2021(in millions USD) (Inherited Diseases, Thrombophilia, Pharmacogenomics, Total genetic 
testing market)

Table 7-10: Diagnostic Inherited Disease PCR and Other NAAT Market by Geographical Distribution, Worldwide, 2016 and 2021 (in millions USD) (United States, Europe, Rest of World, World)

  DIAGNOSTIC PCR MARKET – TRANSPLANTATION DIAGNOSTICS

Table 7-11: Diagnostic Transplantation Diagnostics PCR and Other NAAT Market by Geographical Distribution, Worldwide, 2016 and 
2021 (in millions USD) (United States, Europe, Japan, Rest of World, World)
  
  DIAGNOSTIC PCR MARKET

Table 7-12: PCR and Other NAAT Blood Screening Market, by Geographical Distribution, Worldwide, 2016 and 2021 (in millions USD) 
(United States, Europe, Japan, China, Latin America, Rest of World, Total)

CHAPTER 8: COMPANY PROFILES

ABBOTT LABORATORIES

Recent Revenue History

Table 8-1: Abbott Revenues (2013 to 2016)

Company Overview – With a Focus on Polymerase Chain Reaction

AGENA BIOSCIENCE, INC.
AGILENT TECHNOLOGIES INC.

Recent Revenue History

Table 8-2: Agilent Technologies Revenues (2014, 2015, 2016)

Company Overview

ALERE INC.

Recent Revenue History

Table 8-3: Alere Inc. Revenues (2014, 2015, and first three quarters of 2016)

Company Overview

AMOY DIAGNOSTICS CO., LTD.

ASURAGEN, INC.

ATLAS GENETICS LTD

AUTOGENOMICS, INC.

BECKMAN COULTER, INC. (A DANAHER CORPORATION COMPANY)

Revenue History

Company Overview

BECTON, DICKINSON AND COMPANY (BD)

Recent Revenue History


Table 8-4: Becton Dickinson Revenues (2014 to 2016)

Company Overview

BIOCARTIS GROUP NV

Recent Revenue History

Table 8-5: Biocartis Revenues (2014 to 2016)

Company Overview

BIOFIRE DIAGNOSTICS, LLC. (ACQUIRED BY BIOMÉRIEUX)


Recent Revenue History and Other Financial Information

Company Overview

BIOMÉRIEUX SA

Recent Revenue History

Table 8-6: bioMérieux Revenues (2013 to 2016)

Company Overview

BIO-RAD LABORATORIES, INC

Recent Revenue History

Table 8-7: Bio-Rad Laboratories Net Sales (2014 to 2016)

Company Overview

BRUKER CORPORATION

Recent Revenue History

Table 8-8: Bruker Corporation Revenues (2013 - 2016)

Company Overview

CANON BIOMEDICAL

CEPHEID (A DANAHER COMPANY)

Recent Revenue History

Table 8-9: Cepheid Revenues (2013 - 2015)

Company Overview

CURETIS

Recent Revenue History

Table 8-10: Curetis Revenues (2014, 2015, and first three quarters of 2016)

Company Overview

DIASORIN S.P.A.

Recent Revenue History

Table 8-11: DiaSorin Revenues (2015 and 2016)

Company Overview

EIKEN CHEMICAL CO., LTD.

Recent Revenue History

Table 8-12: Eiken Chemical Co., Ltd. Revenues (FY2014 - FT 2016)

Company Overview

ELITECHGROUP

GENEPOC INC.

GENMARK DIAGNOSTICS, INC.

Recent Revenue History

Table 8-13: GenMark Diagnostics Revenue (2013-2016)

Company Overview

GENOMIC HEALTH, INC.

Recent Revenue History

Table 8-14: Genomic Health Revenues (2014 to 2016)

Company Overview

GRIFOLS

Recent Revenue History

Table 8-15: Grifols Revenues (2015 and 2016)

Company Overview

HOLOGIC, INC.

Recent Revenue History

Table 8-16: Hologic Revenues (FY2014 - FY 2016)

Company Overview

INVIVOSCRIBE TECHNOLOGIES, INC.

JANSSEN DIAGNOSTICS (DIVISION OF JANSSEN PHARMACEUTICA NV)

LUMINEX CORPORATION

Recent Revenue History

Table 8-17: Luminex Corporation Revenues (2014 - 2016)

Company Overview

MAST GROUP

MERIDIAN BIOSCIENCE, INC.

Recent Revenue History

Table 8-18: Meridian Bioscience, Inc. Revenues (FY2014 - FT 2016)

Company Overview

MULTIPLICOM NV (PART OF AGILENT TECHNOLOGIES)

QIAGEN N.V.

Recent Revenue History

Table 8-19: QIAGEN Revenues (2014, 2015, 2016)

Company Overview

QUANDX INC.

QUANTUMDX GROUP

QUIDEL, INC.

Recent Revenue History

Table 8-20: Quidel Revenues (2014 - 2016)

Company Overview

QVELLA CORPORATION

RAINDANCE TECHNOLOGIES, INC. (ACQUIRED BY BIO-RAD LABORATORIES)

ROCHE

Recent Revenue History

Table 8-21: Roche Revenues (2015 - 2016) (mCHF)

Table 8-22: Roche Revenues (2015 - 2016) (mUSD)

Company Overview

SIEMENS HEALTHINEERS

Recent Revenue History

Table 8-23: Siemens Revenues (2015 - 2016) (in millions of euros)

Company Overview

SPARTAN BIOSCIENCE INC

STAT-DIAGNOSTICA

T2 BIOSYSTEMS, INC.

Recent Revenue History

Table 8-24: T2 Biosystems, Inc. Revenues (2014-2016)

Company Overview

THERMO FISHER SCIENTIFIC, INC.

Recent Revenue History

Table 8-25: Thermo Fisher Scientific Revenues (2014-2016)

Company Overview





In this report, {{keyword[keywordTextProperty]}} appears {{keyword[keywordCountProperty]}} times. {{searchResults.STATRESULT.SUMMARY.KW[keywordTextProperty]}} appears {{searchResults.STATRESULT.SUMMARY.KW[keywordCountProperty]}} times.

We were unable to search inside this report.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.